Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS

Nat Rev Neurol. 2013 Feb;9(2):72-3. doi: 10.1038/nrneurol.2012.277. Epub 2013 Jan 22.

Abstract

2012 witnessed important developments for multiple sclerosis, including successful phase III trials of novel oral therapeutics and identification of the potassium channel KIR4.1 as an autoimmune target. Additionally, the lung was highlighted as an important site for immune-cell programming, and the relevance of a TNF receptor variant was clarified.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Dimethyl Fumarate
  • Fumarates / adverse effects
  • Fumarates / therapeutic use
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / genetics
  • Multiple Sclerosis / metabolism
  • Multiple Sclerosis / physiopathology
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Potassium Channels, Inwardly Rectifying / drug effects
  • Quinolones / therapeutic use
  • Receptors, Tumor Necrosis Factor, Type I / genetics
  • Receptors, Tumor Necrosis Factor, Type I / physiology
  • T-Lymphocytes / drug effects

Substances

  • Fumarates
  • Immunosuppressive Agents
  • Kcnj10 (channel)
  • Potassium Channels, Inwardly Rectifying
  • Quinolones
  • Receptors, Tumor Necrosis Factor, Type I
  • laquinimod
  • Dimethyl Fumarate